Istodax (romidepsin)

Updated: Dec 8, 2009
Brand Name: Istodax
Generic Name: romidepsin
Code Name: depsipeptide
Company: Celgene
FDA Clinical Phase: 2

Description:

Istodax is a bicyclic depsipeptide antibiotic that binds and inhibits an enzyme known as histone deacetylase (HDAC). It alters the production of protein from DNA, inhibits the cell cycle, and causes cancer cells to die. Istodax, received FDA approval in November 2009 for the treatment of cutaneous T-cell lymphoma. Clinical trials studying the effects of Istodax and Velcade (bortezomib) in multiple myeloma are underway.

Clinical Trials:
For a list of clinical trials studying Istodax for the treatment of multiple myeloma, see ClinicalTrials.gov.

Official Web site for Istodax: http://www.istodax.com/

Tags: , ,

Related Articles: